Symbols

MRVI

Maravai·NASDAQ

--(--)

MRVI fundamentals

MRVI Q4 2025 Earnings

Maravai (MRVI) released its earnings on Feb 25, 2026: revenue was 49.87M (YoY -11.83%), beat estimates; EPS was -0.04 (YoY +33.33%), beat estimates.

Revenue / YoY

49.87M

-11.83%

EPS / YoY

-0.04

+33.33%

Report date

Feb 25, 2026

MRVI Earnings Call Summary for Q4,2025

Revenue recovery: Q4 2025 revenue (ex-COVID) up 18% YoY, with 2026 guidance of $200-210M (+8-13% YoY).
Profitability turnaround: Q4 2025 EBITDA positive after 4 quarters of losses, with 2026 EBITDA guidance of $18-20M.
Gross margin expansion: 1,200bps improvement expected in 2026, driven by restructuring and GMP product mix.
Strategic momentum: ModTail technology generating $0.5M+ in 2025, and >$1.2M in GMP enzyme orders booked for 2026.
Operational efficiency: $65M+ annualized cost savings achieved, with 13%+ OpEx decline in 2026.

Earnings

EPS

Revenue

Revenue & Expenses

MRVI has released its 2025 Q4 earnings report, with revenue of 49.87M, reflecting a YoY change of -11.83%, and net profit of -63.02M, showing a YoY change of -36.79%. The Sankey diagram below clearly presents MRVI's revenue sources and cost distribution.

Key Indicators

Maravai (MRVI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Maravai (MRVI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Maravai (MRVI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Maravai (MRVI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown